Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris by Oliveira, Haroldo Cesar et al.
ORIGINAL RESEARCH
published: 02 April 2019
doi: 10.3389/fcimb.2019.00083
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 April 2019 | Volume 9 | Article 83
Edited by:
Priya Uppuluri,




Isfahan University of Medical
Sciences, Iran
Hadis Jafarian,









Department of Microbiology, Institute
of Biomedical Sciences, University of
São Paulo, São Paulo, Brazil
Specialty section:
This article was submitted to
Fungal Pathogenesis,
a section of the journal
Frontiers in Cellular and Infection
Microbiology
Received: 20 November 2018
Accepted: 11 March 2019
Published: 02 April 2019
Citation:
de Oliveira HC, Monteiro MC,
Rossi SA, Pemán J, Ruiz-Gaitán A,
Mendes-Giannini MJS, Mellado E and
Zaragoza O (2019) Identification of
Off-Patent Compounds That Present
Antifungal Activity Against the
Emerging Fungal Pathogen Candida
auris.
Front. Cell. Infect. Microbiol. 9:83.
doi: 10.3389/fcimb.2019.00083
Identification of Off-Patent
Compounds That Present Antifungal
Activity Against the Emerging Fungal
Pathogen Candida auris
Haroldo Cesar de Oliveira 1,2, Maria Candida Monteiro 1, Suélen Andreia Rossi 1†,
Javier Pemán 3,4, Alba Ruiz-Gaitán 4, Maria José Soares Mendes-Giannini 2,
Emilia Mellado 1* and Oscar Zaragoza 1*
1Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain, 2 Laboratório
de Micologia Clínica, Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual
Paulista (UNESP), Araraquara, Brazil, 3Hospital Universitari i Politécnic La Fe, Valencia, Spain, 4 Instituto de Investigación
Sanitaria La Fe, Valencia, Spain
Candida auris is an emerging fungal pathogen of great concern among the scientific
community because it is causing an increasing number of hospital outbreaks of difficult
management worldwide. In addition, isolates from this species frequently present
reduced susceptibility to azole and echinocandin drugs. For this reason, it is necessary
to develop new antifungal strategies to better control the disease caused by this yeast. In
this work, we screened drugs from the Prestwick chemical library, which contains 1,280
off-patent compounds that are already approved by the Food and Drug Administration,
with the aim of identifying molecules with antifungal activity against C. auris. In an initial
screening, we looked for drugs that inhibited the growth of three different C. auris
strains and found 27 of them which it did so. Ten active compounds were selected
to test the susceptibility profile by using the EUCAST protocol. Antifungal activity was
confirmed for seven drugs with MICs ranging from 0.5 to 64 mg/L. Some of these drugs
were also tested in combination with voriconazole and anidulafungin at sub-inhibitory
concentrations. Our results suggest synergistic interactions between suloctidil and
voriconazole with fractional inhibitory concentration index (FICI) values of 0.11 to 0.5
and between ebselen and anidulafungin (FICI, 0.12 to 0.44). Our findings indicate that
drug repurposing could be a viable alternative to managing infections by C. auris.
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INTRODUCTION
Infections caused by fungi are an increasing threat for immunosuppressed patient, and their
incidence has risen in the last few decades (Low and Rotstein, 2011; Brown et al., 2012; Pilmis
et al., 2016). Invasive fungal diseases (IFDs) have a high associated mortality rate and economic
cost (Dignani, 2014; Drgona et al., 2014). The fungal pathogens with a higher prevalence
in clinical settings belong to Candida and Aspergillus genera (Sanglard, 2016). However, the
changing epidemiology of the fungal pathogenic species is one of the main challenges in clinical
mycology. This variation is mainly caused by the massive use of antifungals, especially azoles and
echinocandins, which have caused the emergence of species with reduced susceptibility to these
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antifungals (such asCandida krusei,C. glabrata,C. parapsilosis,A.
terreus, Fusarium, Scedosporium, and Lomentospora) (Arendrup
and Perlin, 2014; Berkow and Lockhart, 2017).
Another case that illustrates the epidemiological challenge
of IFDs is the recent emergence of Candida auris as pathogen.
This species is an ascomycete, closely related to C. haemulonii
and C. lusitaniae (Berkow and Lockhart, 2017; Lockhart
et al., 2017a), and has been rarely reported as a causative
agent of IFDs. But in the last 5 years, this fungus has caused
multiple hospital outbreaks worldwide (Calvo et al., 2016;
Schelenz et al., 2016; Sharma et al., 2016; Chow et al., 2018;
de Cassia Orlandi Sardi et al., 2018; Kohlenberg et al., 2018;
Ruiz-Gaitan et al., 2018). The control of these outbreaks has
been difficult for several reasons. First, this yeast can easily be
misidentified as C. haemulonii or C. parapsilosis in laboratories
that do not perform identification through molecular biology
or MALDITOF techniques (Chatterjee et al., 2015; Chowdhary
et al., 2017). Another concern is the difficulty to control and
eradicate the outbreaks from the affected areas. Even rapid
patient to patient transmission has been reported (Schwartz and
Hammond, 2017). For these reasons, some of these outbreaks
have lasted several months or even years until they have been
eliminated from the hospitals (Eyre et al., 2018; Ruiz-Gaitan et al.,
2018). Concerning C. auris antifungal susceptibility profile, most
isolates are intrinsically resistant to fluconazole, and there is also a
high resistance rate reported to echinocandins and amphotericin,
limiting the treatment options that can be administered to
patients (Lockhart et al., 2017b; Sears and Schwartz, 2017;
Kordalewska et al., 2018).
The treatment of fungal infections is frequently limited by the
appearance of intrinsic and secondary resistance and to the low
number of antifungal families available. This is more relevant
to C. auris infection treatment, requiring the design of new
therapeutic strategies. In the last few years, drug repurposing of
“off-patent” drugs has become a feasible alternative to developing
new treatments for invasive fungal diseases. This strategy
offers important advantages compared to the development of
new drugs, such as lower costs and shorter time required to
implement use. In the case of fungal pathogens, drug repurposing
has been successfully used to identify off-patent compounds
against C. albicans and Cryptococcus neoformans (Butts et al.,
2013; Siles et al., 2013; Kim et al., 2015; Wiederhold et al., 2017;
Nixon et al., 2018). In this work, we have attempted to identify
new drugs that present antifungal activity against C. auris.
We have screened the Prestwick Chemical Library, which
contains 1,280 off-patent compounds approved by the FDA
for the treatment of many different diseases. We found several
compounds that could be considered as alternative options to
inhibit the growth of C. auris alone or in combination with
antifungals, confirming that the repurposing of off-patent drugs
is a promising approach to finding antimicrobial molecules.
MATERIALS AND METHODS
Isolates and Culture Conditions
In this work we used five C. auris strains isolated in Spain and
kept at Mycology Reference Laboratory: CL-10093, CL-9998, CL-
10021, CL-10013, and CL-10030; one C. auris from Japan: JCM
15448 (Satoh et al., 2009); and another strain isolated fromKorea:
KCTC 17810 (Kim et al., 2009). All the isolates were propagated
in agar Saboraud plates incubated at 30◦C.
Antifungal Susceptibility Testing
Antifungal susceptibility testing was performed using the
broth microdilution method described by the European
Committee on Antimicrobial Susceptibility Testing, EUCAST
(E.Def 7.3.1 reference method) (Arendrup et al., 2016). The
antifungal agents tested and the range of concentrations used
were: amphotericin B (AmB) (0.03–16 mg/L) (Sigma Aldrich
Quimica, Madrid, Spain), flucytosine (5FC) (0.12–64 mg/L)
(ICN Pharmaceuticals, Orsay, France), fluconazole (FCZ)
(0.12–64 mg/L) (Pfizer SA, Madrid, Spain), itraconazole (ITZ)
(0.015–8 mg/L) (Janssen Pharmaceutical S.A., Madrid, Spain),
voriconazole (VCZ) (0.015–8 mg/L) (Pfizer, S.A., Madrid, Spain),
posaconazole (PSZ) (0.015–8 mg/L) (Schering-plow, Madrid,
Spain), isavuconazole (IVZ) (0.015–8 mg/L) (Astellas Pharma
Inc., Tokyo, Japan), caspofungin (CAS) (0.03–16 mg/L) (Merck
Research Laboratories, Rahway, N.J), micafungin (MCF) (0.004–
2 mg/L) (Astellas Pharma Inc., Tokyo, Japan), and anidulafungin
(ANID) (0.007–4 mg/L) (Merck & Com, Inc, NJ, USA). Candida
auris isolates were cultivated in agar Sabouraud plates at 35◦C
for 24 h and an inoculum at 1–5 × 105 cells/mL was prepared
in distillated water. Then, 100 µL of this inoculum were added
to the library plates (final inoculum = 0.5–2.5 × 105 cells/mL).
The plates were incubated at 35◦C and growth inhibition was
evaluated after 24 h of incubation by measuring the optical
density at 530 nm in a spectrophotometer. The minimal
inhibitory concentration (MIC) was defined as the concentration
that inhibited at least 50% of C. auris growth, except for AmB,
for which MIC evaluated 90% of growth inhibition.
Screening for Active Drugs Against C. auris
The Prestwick Library was purchased from Prestwick Chemical.
The library is composed of 1,280 off-patent drugs in 96-well
plates approved by the Food and Drug Administration (FDA)
and European Medicines Agency (EMA). Each compound was
prepared at 10mM in dimethyl sulfoxide (DMSO). For the
screening, each drug from the library was diluted to a final
concentration of 50µM in RPMI medium containing 2% glucose
buffered at pH 7.0 with 165mM MOPS. In each plate, growth
and sterility controls were added. Candida auris inocula were
suspended in distilled water as described above. The plates were
incubated for 24 h at 35◦C without shaking and the growth
was evaluated by spectrophotometric readings at 530 nm. Active
compounds against C. auris were determined as the ones that
inhibited at least 50% of growth. This primary screening was
performed using threeC. auris strains with different geographical
origin: CL-10093, JCM 15448, and KCTC 17810.
Minimal Inhibitory Concentration of Active
Drugs Against C. auris
The MIC of active compounds against C. auris was determined
following EUCAST methodology (Arendrup et al., 2016).
Antifungal susceptibility plates were prepared with a range of
concentrations from 64 to 0.12 mg/L of each compound in
RPMI. C. auris inocula were prepared as described using the
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TABLE 1 | Antifungal susceptibility test to three C. auris strains.
Antifungal drugs MIC values (mg/L) for the C. auris strains
CL-10093 JCM 15448 KCTC 17810
Amphotericin B (AmB) 0.12 0.12 0.03
Flucytosine (5FC) 0.12 0.12 0.25
Fluconazole (FCZ) >64 64 >64
Itraconazole (ITZ) 0.12 0.12 0.5
Voriconazole (VCZ) 4 4 2
Posaconazole (PSZ) 0.12 0.06 0.5
Isavuconazole (IVZ) 0.06 0.03 2
Caspofungin (CAS) 0.5 0.5 0.5
Micafungin (MCF) 0.125 0.125 0.125
Anidulafungin (AND) 0.03 0.03 0.06
same concentration to inoculate the plates. The plates were
incubated at 35◦C and growth inhibition was evaluated after 24 h
of incubation by spectrophotometrical readings at 530 nm. The
MICs were defined as the concentrations that inhibit at least 50%
(MIC50) or 90% (MIC90) of fungal growth.
Checkerboard Assay
The synergism of three active compounds (suloctidil, ciclopirox
ethanolamine, and ebselen) with VCZ and ANID was also tested
using the checkerboard assay. For this purpose, we used the
following drug concentration ranges: the identified compounds
ranged from 64 to 0.12 mg/L; VCZ ranged from 8 to 0.12
mg/L; and ANID ranged from 0.5 to 0.007 mg/L. To prepare
the plate with the different drug combinations, 50 µL from
each compound concentration were mixed with 50 µL of each
antifungal concentration. Because the drugs and antifungal
stocks were dissolved in DMSO, we ensured that, the DMSO
concentration did not exceed 1% in the assay plate. Checkerboard
plates were inoculated with 100µLC. auris inoculum prepared as
described above. Plates were incubated for 24 h at 35◦C without
shaking. Yeast growth was measured by spectrophotometric
reading at 530 nm. The Fractional Inhibitory Concentration
index (FICI) was calculated according to the equation: 6FIC
= FIC (Compounds) + FIC (VCZ or ANID). The FIC index
represents the sum of the FICs of each drug tested, where the FIC
is determined for each drug by dividing the MIC of each drug
when used in combination by the MIC of each drug when used
alone (Meletiadis et al., 2010). We considered a synergistic effect
when 6FIC was below 0.5 (White et al., 1996).
RESULTS
Antifungal Susceptibility Profile of C. auris
Isolates Against Antifungal Drugs
We first characterized the in vitro antifungal susceptibility of
three C. auris strains from different geographical origins. As
shown in Table 1, all the strains had reduced susceptibility
to all azoles tested, which was more prominent for FCZ and
VCZ. In the case of FCZ, all the isolates were fully resistant
to this antifungal (≥64 mg/L). These isolates were susceptible
to echinocandins, although these antifungals did not fully
inhibit the growth of the yeasts. Echinocandins presented a
significant trailing growth, which was more prominent after 48 h
of incubation (data not shown). All the strains had low MIC
values to 5FC (Table 1) and AmB.
Identification of Active Compounds
Against C. auris
Three clinical C. auris strains (CL-10093, KCTC 17810, and
JCM 15448), were used to identify active compounds among the
1,280 compounds from the Prestwick Chemical Library. In this
initial screening, we identified 27 active compounds belonging
to different classes. Twelve of them inhibited growth ≥90%
of the three C. auris strains and 15 inhibited growth more
than 50% (Table 2). Among them, we found compounds with
different therapeutic effects such as antibacterial, antineoplastic,
antihypertensive, antidepressant, anticonvulsant, antiplatelet,
anti-inflammatory, antipsychotic, and antipruritic. We also
identified 13 antifungal drugs belonging to distinct antifungal
classes that were active against the threeC. auris strains (Table 3).
Antifungal Susceptibility Testing of the
Selected Compounds
Ten active compounds were selected to analyze their activity
against seven C. auris isolates using EUCAST protocol. We
confirmed antifungal activity for 7 compounds: trifluoperazine
dihydrochloride, suloctidil, ciclopirox ethanolamine, ebselen,
tamoxifen citrate, thiethylperazine dimalate, and pyrvinium
pamoate. For three compounds [(-)-MK 801 hydrogen maleate,
rolipram, and guanadrel sulfate] antifungal activity was not
reproduced (Table 4). We did not find noticeable differences in
the susceptibility to the compounds when bothMIC50 andMIC90
were calculated and compared.
Synergism Effect of Suloctidil, Ebselen,
and Ciclopirox Ethanolamine With
Voriconazole and Anidulafungin
Three compounds—suloctidil, ebselen, and ciclopirox
ethanolamine—were selected to test synergism with antifungal
drugs of clinical use. We did not choose FCZ because the isolates
were fully resistant to this drug. VCZ was chosen because,
although having high MIC values against C. auris, it still had
some in vitro activity. In parallel, synergism with ANID was also
tested because echinocandins have become the first treatment
option for invasive candidiasis. The three compounds (64–0.12
mg/L) were combined with VCZ (8–0.12 mg/L) and ANID
(0.5–0.007 mg/L). The same seven isolates used in the MICs
assays were tested in the checkerboard assay. Synergism was
evaluated at 24 h and the FIC was calculated for 50 and 75% of
growth inhibition.
We found that the combination of suloctidil and VCZ was
synergistic against C. auris (FICI values < 0.5 for both 50%
and 75% of growth inhibition, Table 5). The MICs for VCZ
alone were around 2–4 mg/L, and in combination with different
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TABLE 2 | Active compounds at 0.05mM against C. auris strains CL-10093, JCM 15448, and KCTC 17810.
Name mg/L Therapeutic
effect







Chlorhexidine 25 Antibacterial Reacts with the negatively charged microbial cell surface destroying the
integrity of the cell membrane. Also penetrates into the cell and causes
leakage of intracellular components leading to cell death.
98 99 98
Tamoxifen citrate 28 Antineoplastic Act as an anti-estrogen in the mammary tissue, but as an estrogen in
cholesterol metabolism, bone density, and cell proliferation in the
endometrium.
98 98 90
Chloroxine 10 Antibacterial Although the mechanism of action is not fully understood, topical
administration diminishes mitotic activity in the epidermis, reducing







Exerts its action by binding to and chelating trivalent cations inhibiting the
availability of essential co-factors for enzymes. This may lead to a loss of
activity of enzymes that are essential for cellular metabolism, organization of





23 Antibacterial Adsorb onto the negatively charged cell wall of microorganisms, interrupting
normal cell metabolism, leading to cell death, or growth inhibition.
98 97 100
Guanadrel sulfate 10 Antihypertensive Postganglionic adrenergic blocking agent. 97 97 97
Alexidine
dihydrochloride
29 Antibacterial Potent and selective PTPMT1 (Protein Tyrosine Phosphatase Localized to
the Mitochondrion 1) inhibitor.
97 97 97
Rolipram 13 Antidepressant Phosphodiesterase 4 inhibitor with antidepressant properties. 98 97 91
Thonzonium
bromide
29 Antiseptic Monocationic surface-active agent with surfactant and detergent properties. 98 98 98
(-)-MK 801
hydrogen maleate
16 Anticonvulsant N-methyl-D-aspartate receptor antagonist that acts at the NMDA





22 Antibacterial Adsorb onto the negatively charged cell wall of microorganisms, interrupting
normal cell metabolism, leading to cell death or growth inhibition.
96 97 100
Suloctidil 16 Antiplatelet It is not clear the mechanism of action of Suloctidil, but it might act either as




Acts as a glutathione peroxidase mimetic and is thereby able to prevent




19 Antiemetic Act as a dopamine antagonist. 68 90 86
Trifluoperazine
dihydrochloride
24 Antiemetic Act as a dopamine antagonist. 54 88 61
Pyrvinium
pamoate
19 Anthelmintic Interfere with glucose uptake by pinworms, is also thought to inhibit





Bacteriostatic compound, however, the precise mechanism of its action is
unknown.
89 93 93
Hexachlorophene 20 Antiseptic Inhibit the membrane-bound part of the electron transport chain, respiratory





26 Antibacterial Disrupts bacteria cell permeability and also binds to the cytoplasmic
membrane with subsequent formation of complexes and protein




23 Antipsychotic Act as a serotonin receptor antagonist. 74 72 64
Dyclonine
hydrochloride
16 Local anesthetic Binds to activated sodium channels on the neuronal membrane, decreasing
the neuronal membrane’s permeability to sodium ions, leading to an
increased threshold for excitation.
63 63 54
(Continued)
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TABLE 2 | Continued
Name mg/L Therapeutic
effect









21 Anti-fatigue Interacts with the polar heads in the phospholipids membrane influencing in






Act as D2 receptor antagonist. 71 66 72
Artemisinin 14 Antimalarial Act by generating free radicals that in turn damage susceptible proteins,




15 Antipruritic Inhibits nicotinic acetylcholine receptors with the maximum inhibition
potency occurring for the α4β4 subtype.
59 65 51
Sertraline 15 Antidepressant Inhibit the reuptake of serotonin at the presynaptic membrane. 59 88 56
Zotepine 16 Antipsychotic Act as a dopamine antagonist that has a high affinity for D1- and D2-like
receptors.
59 63 56
*Information about the action mechanisms has been extracted from the information provided by Prestwick Chemical, and from DrugBank (https://www.drugbank.ca), and
PubChem (https://pubchem.ncbi.nlm.nih.gov).
TABLE 3 | Antifungal agents active against C. auris strains CL-10093, JCM 15448, and KCTC 17810.







Amphotericin B 46 Binds to ergosterol, an essential component of the fungal cell membrane, causing
depolarization of the membrane and altering cell membrane permeability.
97 97 95
Nystatine 46 97 98 97
Haloprogin 18 The mechanism of action is unknown, but it is thought to be via inhibition of oxygen
uptake and disruption of yeast membrane structure and function.
96 96 83
Ketoconazole 26 88 92 97
Voriconazole 17 87 86 95
Clotrimazole 17 89 93 78
Tioconazole 19 Inhibit cytochrome P450 14-alpha-demethylase, which leads to a decrease in
ergosterol concentration leading to disrupts in the structure and function of the fungal
cell.
86 84 77
Terconazole 26 88 92 97
Econazole nitrate 19 72 82 50
Itraconazole 35 63 68 71
Sertaconazole
nitrate
25 67 92 56
Hexetidine 16 98 98 53
Flucytosine 6 After penetration into the fungal cells, flucytosine is deaminated to its active
metabolite 5-fluorouracil. 5-fluorouracil replaces uracil during fungal RNA synthesis,
thereby inhibiting fungal protein synthesis.
98 95 94
*Information about the action mechanisms has been extracted from the information provided by Prestwick Chemical, and from DrugBank (https://www.drugbank.ca), and
PubChem (https://pubchem.ncbi.nlm.nih.gov).
suloctidil concentrations the MICs values decreased to 0.12–1
mg/L (Figure 1).
In addition, the combination of ebselen and ANID was also
synergistic against this fungal pathogen (FICI values < 0.5 for
75% of growth inhibition) (Table 6). C. auris isolates have ANID
MIC values of 0.12 mg/L. However, when combined with 0.5 or
1 mg/L of ebselen, we observed an increase in the susceptibility
of all the C. auris isolates tested, reaching almost 90% of growth
inhibition (Figure 2).
No synergism was found when ciclopirox ethanolamine was
combined with VCZ or AND.
DISCUSSION
The first isolation and characterization of C. auris as pathogen
was in 2009 when it was isolated from an external ear canal
drainage from a patient in Japan (Satoh et al., 2009). However,
retrospective studies have demonstrated that this yeast has been
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TABLE 4 | MIC50 and MIC90 for the active compounds against C. auris strains.
MIC values (mg/L)
CL-10093 KCTC 17810 JCM 15448 CL-10021 CL-9998 CL-10030 CL-10013
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
(-)-MK 801 hydrogen
maleate
>64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64
Trifluoperazine
dihydrochloride
32 64 32 64 16 32 32 64 32 64 32 64 64 64
Suloctidil 8 8 8 16 4 4 8 8 8 8 4 8 8 8
Ciclopirox ethanolamine 1 4 0.5 2 0.5 1 1 4 1 8 1 1 1 1
Ebselen 4 4 4 4 2 4 4 4 2 4 2 4 4 8
Tamoxifen citrate 16 32 32 64 16 16 32 32 16 32 16 32 16 32
Rolipram >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64
Thiethylperazine dimalate 64 64 64 64 16 32 32 64 32 64 32 64 64 64
Guanadrel sulfate >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64 >64
Pyrvinium pamoate 4 4 2 4 1 2 2 4 2 4 2 4 2 4
TABLE 5 | Fractional Inhibitory Concentration Index for the combination of
voriconazole with suloctidil against C. auris.
C. auris strains FICI
50% 75%
CL-10093 0.37 0.40
JCM 15448 0.34 0.00





the causative agent of diseases since 1996 (Lee et al., 2011). The
frequency of detection of C. auris has increased in recent years,
revealing a rapid and worldwide emergence of this pathogen
(Satoh et al., 2009; Lee et al., 2011; Navalkele et al., 2017;
Bidaud et al., 2018; Eyre et al., 2018; Kohlenberg et al., 2018;
Ruiz-Gaitan et al., 2018) with a strong potential for nosocomial
transmission added to a great capacity for developing multidrug
antifungal resistance (Colombo et al., 2017).
The treatment of C. auris infections represents a great
challenge due to its antifungal susceptibility profile. The majority
of C. auris strains have high MIC values FCZ (>64 mg/L),
suggesting intrinsic resistance to this drug (Chowdhary et al.,
2017). A great number of isolates also exhibits elevated MICs
to VCZ and a few isolates may also be considered resistant
to echinocandins (Chowdhary et al., 2016, 2017; Colombo
et al., 2017). The mechanisms of antifungal resistance in
C. auris remain unknown, although increased tolerance to
antifungal drugs may be partly explained because a significant
portion of C. auris genome encodes transporters belonging
to the ABC and major facilitator superfamilies (Chatterjee
et al., 2015). Furthermore, whole genome sequencing of
multiple isolates from different geographical regions have
demonstrated that the majority of C. auris clinical isolates
present amino acid substitutions at the ERG11 gene, which
has been associated to fluconazole resistance in other Candida
spp (Lockhart et al., 2017b).
The search for new antifungal alternatives is of great
importance due to the urgent need to solve the problem of
resistance in this pathogen. One strategy is drug repurposing
which involves finding new applications for drugs that are already
available for use. This approach results in a rapid application
at a lower cost compared with the development of a new drug
(Corsello et al., 2017). In this work, we describe several off-patent
molecules that present antifungal activity against C. auris.
Using this strategy, we initially found 27 compounds
with activity against C. auris. Among the active compounds,
there were drugs from different therapeutic classes and 13
antifungal drugs (Tables 2, 3). The antifungal activity of seven
of them (trifluoperazine dihydrochloride, suloctidil, ciclopirox
ethanolamine, ebselen, tamoxifen citrate, thiethylperazine
dimalate, pyrvinium pamoate) was confirmed with seven clinical
C. auris isolates.
One of the most active compounds was ebselen, which is an
anti-inflammatory and antioxidant drug currently under clinical
trials for the prevention and treatment of various disorders such
as cardiovascular diseases, arthritis, stroke, atherosclerosis, and
cancer. Ebselen mimics the activity of glutathione peroxidase
and in consequence protects against oxidative damage (Azad
and Tomar, 2014). However, in prokaryotes, ebselen inhibits
the activity of thioredoxin reductase, leading to an increase in
the amount of reactive oxygen species in the cell and decreased
viability (Azad and Tomar, 2014). In the case of fungi, ebselen
is active against FCZ-resistant C. albicans strains (Billack et al.,
2009) and can behave as fungistatic or fungicidal, depending
on the concentrations used in the assays. Furthermore, ebselen
is at least 10-fold more potent than fluconazole. These authors
suggested that the antifungal activity of ebselen could be due to
its interaction with the sulfhydryl group of L-cysteine residues
within the plasma membrane H+-ATPase (Billack et al., 2009).
Other authors have reported that ebselen is active against
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FIGURE 1 | Representative graphs of the synergistic effect of VCZ (ranging concentration: 8–0.12 mg/L) in combination with 2 and 4 mg/L of suloctidil against
C. auris strains by checkerboard assay.
TABLE 6 | Fractional Inhibitory Concentration Index for the combination of
anidulafungin with ebselen against C. auris.
C. auris strains FICI
50% 75%
CL-10093 0.82 0.12
JCM 15448 1.13 0.28





several fungal species [C. albicans, C. glabrata, C. tropicalis,
C. parapsilosis, Cryptococcus neoformans, and C. gattii] at MICs
ranging from 0.015 to 2 mg/L (Thangamani et al., 2017; Eyre
et al., 2018). In vivo studies using Caenorhabditis elegans as
model of infection have shown that ebselen activity is superior
to FCZ, 5FC, and AmB. Furthermore, in fungi, ebselen depletes
intracellular glutathione levels increasing the production of
reactive oxygen species (Thangamani et al., 2017). Our findings
are in agreement with the recent work by Wall et al., who
found that ebselen has antifungal activity against C. auris and
other Candida spp. such as C. lusitaniae, C. krusei, C. albicans,
C. dubliniensis,C. parapsilosis,C. tropicalis, andC. glabrata (Wall
et al., 2018).
Suloctidil was another compound with important activity
against C. auris, with MIC values ranging from 4 to 8 mg/L.
Suloctidil is an antiplatelet drug with reported activity against
C. albicans and C. neoformans (Butts et al., 2013). Suloctidil
is also effective against C. albicans biofilms and inhibits hyphae
formation, one of the most important virulence factor of
C. albicans (Zeng et al., 2017). By using a chemical-genetic profile
approach, it was found that suloctidil interferes with membrane
trafficking and vacuolar biogenesis (Spitzer et al., 2011).
We also found that the anthelmintic drug pyrvinium pamoate
has a noticeable activity againstC. auris, withMIC values ranging
from 1 to 4mg/L against all the strains tested. Pyrvinium pamoate
is synergistic with miconazole against C. albicans biofilms (De
Cremer et al., 2015). Furthermore, pyrvinium pamoate inhibits
the growth of the C. albicans FCZ resistant isochromosome
5L strain, which contains two copies of the left arm of the
chromosome 5, a mechanism that confers resistance to FCZ
(Chen et al., 2015). More recently, it has been shown that
pyrvinium pamoate is active against the black yeast Exophiala
dermatitidis strains and exhibits synergy with ITZ, FCZ, and
PSZ (Gao et al., 2018).
Ciclopirox ethanolamine, with MICs values ranging
from 0.5 to 1 mg/L also presented activity against C. auris.
It is thought that it acts by chelating trivalent cations,
which induces cell permeability alterations (Gupta and
Skinner, 2003). This compound has antifungal activity
against several species, including all clinically relevant
dermatophytes, molds and yeasts, as well as those with
reduced susceptibility to azoles, such as C. glabrata, C. krusei,
and C. guilliermondii (Niewerth et al., 2003).
In addition to the search for new antifungal compounds,
another important tool to fight resistant fungal infection is to
improve the action of the known antifungal drugs currently
used in therapy. One approach is finding molecules or drugs
that act synergistically with known antifungal drugs. In example,
synergy between micafungin and voriconazole has been found
with multiple C. auris strains (Fakhim et al., 2017).
We evaluated the synergism activity of three of the screened
compounds, ebselen, suloctidil, and ciclopirox ethanolamine
with two antifungal drugs, voriconazole and anidulafungin.
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FIGURE 2 | Representative graphs of the synergistic effect of AND (ranging concentration: 0.007–0.5 mg/L) in combination with 0.5 and 1 mg/L of ebselen against
C. auris strains by checkerboard assay.
Ebselen only showed amoderate synergismwith ANID. In our
results, ANID at higher concentrations >0.12 mg/L produced
a growth inhibition of 60–70%, and the addition of ebselen
increased this inhibition to >90%. Wall et al. assayed the
synergism of ebselen with FCZ, AmB, and caspofungin against
planktonic cells and biofilm from C. auris and C. albicans and
they found that only the combination of ebselen with FCZ was
synergic against C. albicans. However, none of the combinations
showed synergism against C. auris (Wall et al., 2018).
The only drug that showed synergism with VCZ was
Suloctidil. The combination with suloctidil decreased the MIC
values for VCZ from 2–4 to 0.12–1 mg/L. Other authors
have found that suloctidil is synergistic with FCZ against
C. neoformans (Spitzer et al., 2011; Butts et al., 2013). As
proposed by Spitzer et al., this combination affects fungal
viability in different ways such as increasing fungal cell
sensitivity to accumulation of intermediates of the ergosterol
pathway, difficulting FCZ export by drug efflux pumps,
and inhibiting import of extracellular ergosterol (Spitzer
et al., 2011), although these hypothesis have not been fully
validated yet.
Our results are in agreement with the recent report by
Wall et al. (2018) in which a similar approach was taken
to identify several compounds with activity against C. auris.
Among the drug hits identified by both studies, four compounds
were common: suloctidil, ebselen, pyrvinium pamoate and
dimethisoquin hydrochloride, suloctidil and ebselen being the
most effective compounds against C. auris (>80% of inhibition).
Wall et al. also showed that ebselen has a broad-spectrum
antifungal activity, being also able to inhibit biofilms of C. auris
and C. neoformans. All these data highlight the potential of
ebselen as an antifungal drug. Our study also revealed the
effectiveness of different drugs from Wall et al. (2018), probably
due to the differences in the concentration of the drugs employed
in the screening (50 vs. 20µM) and to the use of different
C. auris strains.
At this point the in vivo use of these drugs cannot
be anticipated nor can their associated toxicity, because the
concentration required to confer protection against C. aurismay
be different from the one used in current applications. Besides
this limitation, our findings indicate that drug repurposing can
be a very important tool for finding active compounds against
multi-resistant fungal pathogens. In addition, the use of ebselen
or suloctidil in combination with ANID or VCZ, respectively,
warrants further consideration.
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